Marius E. Mayerhoefer, MD, PhD
PET/MRI; PET/CT; MRI; CT
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Medical University of Vienna; PhD, Medical University of Vienna
Radiology - Medical University of Vienna
European School of Radiology Scholarship in Oncologic Imaging - Addenbrooke’s Hospital, University of Cambridge
I am a board-certified radiologist with ten years of experience in cancer imaging. I joined Memorial Sloan Kettering in October 2019.
My clinical focus is on PET/MRI, PET/CT, and MRI of people with lymphoma, myeloma, and leukemia. I serve as Director of PET/MRI and as a member of the Lymphoma Disease Management Team at MSK, working closely with oncologists, radiation oncologists, pathologists, and others to provide the best possible patient care.
I believe that molecular and functional imaging using novel PET radiopharmaceuticals and MRI techniques that capture specific aspects of cancer metabolism are key to a better understanding of tumor biology and the success for personalized and precision medicine. I expect that in the near future, the combination of such quantitative imaging biomarkers with artificial intelligence will enable us to better estimate which patients will benefit from certain types of treatment, and to predict clinical outcomes.
My research on MRI and PET/MRI in oncology has been supported by more than $2 million in grants, and has been published in highly ranked specialty journals such as Clinical Cancer Research and Theranostics. Together with my clinical partners from hematology, oncology, and dermatology, I have also participated in several clinical trials of novel systemic treatments, the results of which have been published in journals such as Blood, Lancet Hematology, and Nature Communications.
I serve on the editorial boards of the journals Investigative Radiology, Cancers, European Radiology, and Cancer Imaging. I am an executive board member of the European Society of Oncologic Imaging (ESOI), the European Imaging Biomarkers Alliance (EIBALL), and a fellow of the International Cancer Imaging Society (ICIS).
I am proud to be a part of MSK and to contribute to this prestigious institution’s reputation of excellence in patient care and research.
Awards and Honors
- Subcommittee Chair for Oncologic Imaging, European Congress of Radiology (2021)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Mayerhoefer’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Marius E. Mayerhoefer discloses the following relationships and financial interests:
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.